Last reviewed · How we verify

Acute pulmonary edema — Treatment Landscape & Competitive Intelligence

Acute pulmonary edema (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Acute pulmonary edema, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Lasix furosemide Generic (originally Hoechst AG) Loop Diuretic [EPC] ATP-binding cassette sub-family G member 2, CDGSH iron-sulfur domain-containing protein 1, G-protein coupled receptor 35 1966-07-01
Frusemide Frusemide Melbourne Health ATP-binding cassette sub-family G member 2, CDGSH iron-sulfur domain-containing protein 1, G-protein coupled receptor 35

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Generic (originally Hoechst AG) · 1 drug in Acute pulmonary edema
  2. Melbourne Health · 1 drug in Acute pulmonary edema

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Acute pulmonary edema:

Cite this brief

Drug Landscape (2026). Acute pulmonary edema — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/acute-pulmonary-edema. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing